Sapir Pinhas1,2, Idit Tessler3,4, Luba Pasherstnik Bizer2,5, Khaled Khalilia2,5, Meir Warman1,2, Meital Adi2,5, Doron Halperin1,2, Oded Cohen1,2. 1. Department of Otolaryngology, Head and Neck Surgery, Kaplan Medical Center, Rehovot, Israel. 2. Hadassah Medical School, Hebrew University, Jerusalem, Israel. 3. Department of Otolaryngology, Head and Neck Surgery, Kaplan Medical Center, Rehovot, Israel. idit.tessler@gmail.com. 4. Hadassah Medical School, Hebrew University, Jerusalem, Israel. idit.tessler@gmail.com. 5. Department of Radiology, Kaplan Medical Center, Rehovot, Israel.
Abstract
PURPOSE: Managing intermediate thyroid nodules remains challenging. The CUT score is an Italian metanalysis-based cytologic (SIAPEC-IAP) scoring system, designed to assist clinicians. However, it was never evaluated against the Bethesda system for reporting thyroid cytopathology (BSRTC). This study aims to validate its utility for BSRTC III and IV nodules in a non-Italian population. METHODS: We collected all BSRTC III and IV thyroid nodules with a documented final pathology between 2010 and 2020. We calculated the C + U components of the CUT score using retrospective clinical (C) data collection and reevaluation of preoperative sonography (U) examination. The cytology (T) component which originally referred to the five-tiered SIAPEC-IAP cytologic classification was replaced by the corresponding BSRTC categories. Optimal test performances were calculated using receiver operating characteristic (ROC) curve analysis. Data were analyzed twice with considering of NIFTP as benign and as malignant. RESULTS: After exclusions, 62 nodules from 61 patients were included (50% BSRTC III, 50% BSRTC IV). Malignant nodules demonstrated a significantly higher C + U score compared with benign in both categories. The C + U cutoff value for BSRTC III was 5.25 (sensitivity and specificity of 69.23% and 66.67%, respectively, AUC = 0.72, p-value = 0.016), and 5.75 for BSRTC IV (sensitivity and specificity of 85.7% and 76.5%, respectively, AUC = 0.84, p-value < 0.001). CONCLUSION: Our study suggests that the CUT score is applicable for both BSRTC III and IV nodules, and highlights the need for internal validations, since the cutoffs found were higher than previously reported.
PURPOSE: Managing intermediate thyroid nodules remains challenging. The CUT score is an Italian metanalysis-based cytologic (SIAPEC-IAP) scoring system, designed to assist clinicians. However, it was never evaluated against the Bethesda system for reporting thyroid cytopathology (BSRTC). This study aims to validate its utility for BSRTC III and IV nodules in a non-Italian population. METHODS: We collected all BSRTC III and IV thyroid nodules with a documented final pathology between 2010 and 2020. We calculated the C + U components of the CUT score using retrospective clinical (C) data collection and reevaluation of preoperative sonography (U) examination. The cytology (T) component which originally referred to the five-tiered SIAPEC-IAP cytologic classification was replaced by the corresponding BSRTC categories. Optimal test performances were calculated using receiver operating characteristic (ROC) curve analysis. Data were analyzed twice with considering of NIFTP as benign and as malignant. RESULTS: After exclusions, 62 nodules from 61 patients were included (50% BSRTC III, 50% BSRTC IV). Malignant nodules demonstrated a significantly higher C + U score compared with benign in both categories. The C + U cutoff value for BSRTC III was 5.25 (sensitivity and specificity of 69.23% and 66.67%, respectively, AUC = 0.72, p-value = 0.016), and 5.75 for BSRTC IV (sensitivity and specificity of 85.7% and 76.5%, respectively, AUC = 0.84, p-value < 0.001). CONCLUSION: Our study suggests that the CUT score is applicable for both BSRTC III and IV nodules, and highlights the need for internal validations, since the cutoffs found were higher than previously reported.
Authors: M Tonacchera; P Agretti; T Rago; G De Marco; F Niccolai; A Molinaro; M Scutari; A Candelieri; D Conforti; R Musmanno; G Di Coscio; F Basolo; P Iacconi; P Miccoli; A Pinchera; P Vitti Journal: J Endocrinol Invest Date: 2011-10-04 Impact factor: 4.256
Authors: Darya Chudova; Jonathan I Wilde; Eric T Wang; Hui Wang; Nusrat Rabbee; Camila M Egidio; Jessica Reynolds; Ed Tom; Moraima Pagan; C Ted Rigl; Lyssa Friedman; C Charles Wang; Richard B Lanman; Martha Zeiger; Electron Kebebew; Juan Rosai; Giovanni Fellegara; Virginia A LiVolsi; Giulia C Kennedy Journal: J Clin Endocrinol Metab Date: 2010-09-08 Impact factor: 5.958
Authors: T S Greaves; M Olvera; B D Florentine; A S Raza; C J Cobb; D D Tsao-Wei; S Groshen; P Singer; J Lopresti; S E Martin Journal: Cancer Date: 2000-12-25 Impact factor: 6.860
Authors: Richard T Kloos; Jessica D Reynolds; P Sean Walsh; Jonathan I Wilde; Edward Y Tom; Moraima Pagan; Catalin Barbacioru; Darya I Chudova; Mei Wong; Lyssa Friedman; Virginia A LiVolsi; Juan Rosai; Richard B Lanman; Giulia C Kennedy Journal: J Clin Endocrinol Metab Date: 2013-03-08 Impact factor: 5.958
Authors: Erik K Alexander; Giulia C Kennedy; Zubair W Baloch; Edmund S Cibas; Darya Chudova; James Diggans; Lyssa Friedman; Richard T Kloos; Virginia A LiVolsi; Susan J Mandel; Stephen S Raab; Juan Rosai; David L Steward; P Sean Walsh; Jonathan I Wilde; Martha A Zeiger; Richard B Lanman; Bryan R Haugen Journal: N Engl J Med Date: 2012-06-25 Impact factor: 91.245
Authors: Guido M Sclabas; Gregg A Staerkel; Suzanne E Shapiro; Bruno D Fornage; Steven I Sherman; Rena Vassillopoulou-Sellin; Jeffrey E Lee; Douglas B Evans Journal: Am J Surg Date: 2003-12 Impact factor: 2.565
Authors: Yuri E Nikiforov; David L Steward; Toni M Robinson-Smith; Bryan R Haugen; Joshua P Klopper; Zhaowen Zhu; James A Fagin; Mercedes Falciglia; Katherine Weber; Marina N Nikiforova Journal: J Clin Endocrinol Metab Date: 2009-03-24 Impact factor: 5.958
Authors: Lodovico Rosato; Nicola Avenia; Paolo Bernante; Maurizio De Palma; Giuseppe Gulino; Pier Giorgio Nasi; Maria Rosa Pelizzo; Luciano Pezzullo Journal: World J Surg Date: 2004-02-17 Impact factor: 3.352